Reminder: We are holding our Triple Play Income 2022 Review/2023 Preview Session today at 4:00 PM Eastern. You can register for the live webinar session here. We will review our progress from 2022 and take look at market for income stocks in 2023. We hope you can join us, but if not, the session will be recorded and posted on the member site.




Blackstone (BX):  94.43


We will discuss Blackstone in more depth during our live Review Session this afternoon. The stock price has retreated to the mid-90s and our 105 call is now worthless. Let’s roll it out one more week and down 5 points for a small credit.


ACTION:  Roll the BX 10 Feb 105 call to the BX 17 Feb 100 call for a net credit of around 0.58 to 0.65

Buy to close BX 10 Feb 105 call

Sell to open BX 17 Feb 100 call




Gilead Sciences (GILD):  86.15


Gilead turned in a strong earnings report last week. Q4 EPS of $1.67 beat estimates by 0.16 and revenues of $7.39B grew by 2.1% year-over-year. The company reported sales success across a number of their key drug product lines and upped their guidance for 2023. Gilead also announced a 2.7% dividend increase to 0.75/share per quarter … that’s another good sign that GILD’s business is healthy heading into 2023.


Healthcare stocks with positive earnings are getting rewarded by Wall Street. We can continue to roll our puts out for more credit until we approach the next ex-dividend date in March.


ACTION:  ROLL the GILD 10 Feb 84 put to the 24 Feb 85 put for a net credit of around 0.95 to .99

Buy to close GILD 10 Feb 84 put

Sell to open GILD 24 Feb 85 put

Receive the latest news

Subscribe To Our Daily Newsletter

Get notified about new articles, special events, training, and much more

Like What You See?

Leave your info below to get more options and trading ideas to your inbox

Yes, send me news to my inbox.